DurAVR isn't anywhere near the finish line yet.
Besides, the competition doesn't have to acquire a company with a better product - all they have to do is maintain market share, and they have their own R&D, their industry momentum and reputation to help with that.
Hospitals will want a product backed by a $multi-billion company: after all, if a heart-valve product is is implanted with adverse consequences, the lawyers have to sue someone for multi-millions, and we don't want that to be our hospital.
I'm not being a wet blanket for the fun of it. But there's an awful lot of chickens being counted around here.
P
Video, page-38
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.85 |
Change
0.860(8.61%) |
Mkt cap ! $229.3M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.90 | $10.00 | $498.3K | 46.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 480 | $10.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.88 | 87 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |